Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
49 PLN | +0.31% | -3.54% | -14.78% |
Sales 2024 * | 152M 37.7M | Sales 2025 * | 218M 54.02M | Capitalization | 1.13B 280M |
---|---|---|---|---|---|
Net income 2024 * | -161M -39.98M | Net income 2025 * | -119M -29.55M | EV / Sales 2024 * | 6.95 x |
Net cash position 2024 * | 73.62M 18.28M | Net Debt 2025 * | 18.41M 4.57M | EV / Sales 2025 * | 5.28 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | +0.31% | ||
1 week | -3.54% | ||
Current month | -11.23% | ||
1 month | -10.91% | ||
3 months | -10.26% | ||
6 months | -22.83% | ||
Current year | -14.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 49 | +0.31% | 2 317 |
24-04-29 | 48.85 | -0.91% | 10,679 |
24-04-26 | 49.3 | -1.00% | 4,319 |
24-04-25 | 49.8 | +0.10% | 3,262 |
24-04-24 | 49.75 | -2.07% | 4,107 |
Delayed Quote Warsaw S.E., April 30, 2024 at 08:12 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.78% | 280M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.01% | 22.18B | |
-16.67% | 21.2B | |
-9.37% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- RVU Stock